$MTEM
Molecular Templates, Inc.

2016 Q1 Form 10-Q Financial Statement

#000156459016018045 Filed on May 05, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q4 2015 Q1
Revenue $0.00 $65.87M $3.680M
YoY Change -100.0% 1689.95% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.250M $2.250M $2.620M
YoY Change -14.12% -14.12% -0.38%
% of Gross Profit
Research & Development $6.005M $11.37M $10.68M
YoY Change -43.77% 32.06% 10.64%
% of Gross Profit
Depreciation & Amortization $190.0K $250.0K $240.0K
YoY Change -20.83% -10.71% -38.46%
% of Gross Profit
Operating Expenses $8.254M $13.62M $13.30M
YoY Change -37.92% 21.28% 8.21%
Operating Profit -$8.254M -$9.615M
YoY Change -14.15% 11.72%
Interest Expense $32.00K $30.00K $33.00K
YoY Change -3.03% 50.0% -17.5%
% of Operating Profit
Other Income/Expense, Net $370.0K $17.43M -$1.572M
YoY Change -123.54% 1017.31% -207.89%
Pretax Income -$7.850M $69.71M -$11.15M
YoY Change -29.6% -1269.63% 56.84%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$7.852M $69.71M -$11.15M
YoY Change -29.6% -1268.9% 56.9%
Net Earnings / Revenue 105.83% -303.1%
Basic Earnings Per Share -$0.11 $0.98 -$0.17
Diluted Earnings Per Share -$0.11 $0.86 -$0.17
COMMON SHARES
Basic Shares Outstanding 71.49M 66.73M
Diluted Shares Outstanding 71.49M 66.73M

Balance Sheet

Concept 2016 Q1 2015 Q4 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $38.00M $48.70M $78.90M
YoY Change -51.84% -16.89% 9.58%
Cash & Equivalents $11.21M $4.245M $21.06M
Short-Term Investments $39.10M $57.80M
Other Short-Term Assets $1.900M $2.600M $1.200M
YoY Change 58.33% 225.0% -7.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $40.60M $53.17M $82.10M
YoY Change -50.55% -20.26% 4.6%
LONG-TERM ASSETS
Property, Plant & Equipment $300.0K $333.0K $503.0K
YoY Change -40.36% -40.22% -20.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $4.200M
YoY Change -70.83%
Other Assets $200.0K $166.0K $1.201M
YoY Change -83.35% -85.68% 3.62%
Total Long-Term Assets $500.0K $499.0K $5.905M
YoY Change -91.53% -70.92% -63.51%
TOTAL ASSETS
Total Short-Term Assets $40.60M $53.17M $82.10M
Total Long-Term Assets $500.0K $499.0K $5.905M
Total Assets $41.10M $53.67M $88.01M
YoY Change -53.3% -21.53% -7.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.600M $725.0K $1.809M
YoY Change -11.55% -65.04% -54.84%
Accrued Expenses $4.000M $3.269M $4.196M
YoY Change -4.67% 2.8% 5.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.575M $10.83M $28.98M
YoY Change -80.76% -58.31% 2.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.600M $2.000M $78.90M
YoY Change -97.97% -96.99% -17.38%
Total Long-Term Liabilities $1.600M $2.000M $78.90M
YoY Change -97.97% -96.99% -17.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.575M $10.83M $28.98M
Total Long-Term Liabilities $1.600M $2.000M $78.90M
Total Liabilities $7.178M $12.82M $107.9M
YoY Change -93.35% -86.12% -12.75%
SHAREHOLDERS EQUITY
Retained Earnings -$337.3M -$329.4M -$384.4M
YoY Change -12.26% -11.74% 7.14%
Common Stock $371.2M $370.3M $364.5M
YoY Change 1.82% 6.01% 10.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $33.87M -$27.32M -$19.89M
YoY Change
Total Liabilities & Shareholders Equity $41.05M $53.67M $88.01M
YoY Change -53.36% -21.53% -7.05%

Cashflow Statement

Concept 2016 Q1 2015 Q4 2015 Q1
OPERATING ACTIVITIES
Net Income -$7.852M $69.71M -$11.15M
YoY Change -29.6% -1268.9% 56.9%
Depreciation, Depletion And Amortization $190.0K $250.0K $240.0K
YoY Change -20.83% -10.71% -38.46%
Cash From Operating Activities -$10.63M -$7.570M -$3.840M
YoY Change 176.82% -25.27% -188.07%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $38.00K
YoY Change -100.0% -100.0% 58.33%
Acquisitions
YoY Change
Other Investing Activities $12.24M $3.420M -$11.96M
YoY Change -202.34% -50.29% 129.12%
Cash From Investing Activities $12.24M $3.420M -$12.00M
YoY Change -202.0% -50.22% 129.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $13.00K $28.10M
YoY Change -99.95% 8044.93%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00K 30.00K 28.51M
YoY Change -99.96% -92.68% 8045.71%
NET CHANGE
Cash From Operating Activities -10.63M -7.570M -3.840M
Cash From Investing Activities 12.24M 3.420M -12.00M
Cash From Financing Activities 10.00K 30.00K 28.51M
Net Change In Cash 1.620M -4.120M 12.67M
YoY Change -87.21% 44.56% -2490.57%
FREE CASH FLOW
Cash From Operating Activities -$10.63M -$7.570M -$3.840M
Capital Expenditures $0.00 $0.00 $38.00K
Free Cash Flow -$10.63M -$7.570M -$3.878M
YoY Change 174.11% -25.2% -189.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10680000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
71000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
370236000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q1 us-gaap Liabilities
Liabilities
7178000
CY2016Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1494000
CY2016Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
109000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Liabilities
Liabilities
12823000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
131000
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5575000
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
72000
CY2016Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1000
CY2015Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1864000
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10828000
CY2016Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
371091000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-21000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8254000
CY2016Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
32000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
370000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-7852000
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7830000
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2015Q1 thld Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-5255000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-719000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6005000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2249000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
8254000
CY2016Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71488000
CY2016Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71488000
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
185000
CY2016Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-9000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
843000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1421000
CY2016Q1 thld Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-1114000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
436000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
838000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-265000
CY2016Q1 thld Increase Decrease In Accrued Clinical And Development Liabilities
IncreaseDecreaseInAccruedClinicalAndDevelopmentLiabilities
-3509000
CY2015Q1 thld Increase Decrease In Accrued Clinical And Development Liabilities
IncreaseDecreaseInAccruedClinicalAndDevelopmentLiabilities
2250000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2582000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1016000
CY2016Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
22000
CY2015Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
18000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3681000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-337292000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71462059
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71511425
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71511425
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71462059
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2616000
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41050000
CY2016Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q1 us-gaap Contracts Revenue
ContractsRevenue
3681000
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2016Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
40846000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-329440000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53669000
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
33872000
CY2016Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
13296000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9615000
CY2015Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
33000
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1572000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-11154000
CY2015Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11156000
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2015Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66732000
CY2015Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66732000
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
239000
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
206043
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11561093
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11434385
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7085144
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.77
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.54
CY2016Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
26754000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10627000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3841000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
38000
CY2016Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
7495000
CY2015Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
32899000
CY2015Q1 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
1997000
CY2016Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
19731000
CY2015Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
18939000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
12236000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
28514000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-12001000
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28514000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1622000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
12672000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8391000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21063000
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1864000
CY2016Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1494000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
843000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1421000
CY2016Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6300000
CY2016Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9032136
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2735000
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.78
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.01
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.03
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.65
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M11D
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y6M
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y8M27D
CY2016Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
CY2016Q1 us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
0
CY2015Q1 us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
0
CY2016Q1 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
37894000
CY2015Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
48510000
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2016Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
26755000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
39112000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
22000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
39091000
CY2016Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2015Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2016Q1 thld Weighted Average Maturity For Available For Sale Securities
WeightedAverageMaturityForAvailableForSaleSecurities
P3M
CY2016Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
11640000
CY2016Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
4000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
578000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
260000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
838000
CY2015Q4 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
40
CY2015Q4 us-gaap Severance Costs1
SeveranceCosts1
2500000
CY2015Q4 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
200000

Files In Submission

Name View Source Status
0001564590-16-018045-index-headers.html Edgar Link pending
0001564590-16-018045-index.html Edgar Link pending
0001564590-16-018045.txt Edgar Link pending
0001564590-16-018045-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
thld-10q_20160331.htm Edgar Link pending
thld-20160331.xml Edgar Link completed
thld-20160331.xsd Edgar Link pending
thld-20160331_cal.xml Edgar Link unprocessable
thld-20160331_def.xml Edgar Link unprocessable
thld-20160331_lab.xml Edgar Link unprocessable
thld-20160331_pre.xml Edgar Link unprocessable
thld-ex101_211.htm Edgar Link pending
thld-ex102_177.htm Edgar Link pending
thld-ex103_145.htm Edgar Link pending
thld-ex311_7.htm Edgar Link pending
thld-ex312_10.htm Edgar Link pending
thld-ex321_9.htm Edgar Link pending
thld-ex322_8.htm Edgar Link pending